UNSPSC 51383102: Oxaceprol

This classification denotes a nonsteroidal antiinflammatory drug, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q0XV76B96L. European Medicines Agency schedules Oxaceprol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09483MIG. Oxaceprol generally arises in the molecular formula C7H11NO4. The term OXACEPROL is an International Nomenclature of Cosmetic Ingredients designation. OXACEPROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule oxaceprol under HS 29339990 and SITC 51577. As of Q4 2014, OXACEPROL remains the US FDA Preferred Term for this commodity. Oxaceprol bears US NLM identifiers UMLS ID C0064164 and NCI Concept Code C90905. SMILES: OC1CC(NC1)C(=O)O.

UNSPSC 51383102 Oxaceprol, a Commodity code, nominally covers a specific pharmaceutical ingredient, but recent state and local solicitations under this code reflect a broader pharmaceutical supply and health-initiative portfolio—including naloxone procurement, drug deactivation systems, generic multi-source pharmaceuticals, and over-the-counter products. State and local governments buying under this code range from county health departments managing community health initiatives and emergency-response inventories to state health agencies coordinating multi-jurisdictional pharmaceutical procurement through cooperative purchasing vehicles. Seminole County, Florida, for example, procures naloxone and safe drug deactivation systems to support community health operations, while the Texas Health and Human Services Commission and Minnesota's multistate cooperative purchasing alliance (MMCAP) solicit broader pharmaceutical supply chains. The actual work involves establishing supplier relationships, managing regulatory compliance including Drug Supply Chain Security Act certification and current Good Manufacturing Practices standards, and fulfilling quarterly or ongoing product deliveries through authorized wholesaler networks.

Recent opportunities span Florida, Texas, and Minnesota-led multistate purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, requiring quarterly deliveries and fixed-fee pricing with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels, framing a future formal procurement strategy rather than an immediate award opportunity. Minnesota's MMCAP issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026, requiring NDC-level product detail, compliance certification, relationships with three authorized wholesalers, and contracts effective July 1, 2026 across participating state and local facilities including Oregon. Vendors must maintain $5 million commercial general liability insurance, $2 million network security and privacy liability, and $2 million professional liability, with performance penalties of $200 to $1,500 per violation.